What Is FOXO4-DRI? A Senolytic Research Peptide Explained

FOXO4-DRI is a synthetic D-retro-inverso (DRI) peptide designed to disrupt the FOXO4–p53 protein interaction inside senescent cells, and it is studied as a senolytic research tool in cellular-senescence biology. It is investigated for its ability to selectively trigger programmed cell death in senescent (“aged”) cells while sparing healthy ones in laboratory and animal models. This article is for educational purposes only. FOXO4-DRI is discussed strictly as a subject of preclinical research. It is not a drug, supplement, or therapy, and nothing here describes use in humans.

Quick facts

• Class: D-retro-inverso (DRI) peptide — a senolytic research tool
• Molecular target: the FOXO4–p53 protein–protein interaction
• Research focus: cellular senescence and selective clearance of senescent cells
• Status: preclinical / in-vitro and animal research only; not approved for any use

What is FOXO4-DRI?

FOXO4-DRI is a small engineered peptide first described by Baar and colleagues in 2017. The “DRI” stands for D-retro-inverso, a design in which the amino-acid sequence is reversed and built entirely from D-amino acids (the mirror-image form of the naturally occurring L-amino acids). This configuration is intended to preserve the shape that engages the target while making the peptide more resistant to enzymatic breakdown in laboratory systems. The peptide is derived from a region of FOXO4, a transcription factor that researchers have linked to the survival of senescent cells — cells that have stopped dividing but resist dying, and that accumulate in tissues over time in animal models.

What does the research show?

The foundational study is Baar et al. (2017), published in Cell. The authors reported that FOXO4 helps keep the tumor-suppressor protein p53 sequestered in senescent cells, which blocks p53 from triggering apoptosis (programmed cell death). By introducing a FOXO4 peptide that perturbs the FOXO4–p53 interaction, the researchers observed selective induction of apoptosis in senescent cells, with neighboring non-senescent cells largely unaffected in their cell and mouse models. In that work, FOXO4-DRI was reported to counteract effects of chemotherapy-induced senescence and to influence markers of tissue function in naturally aged and progeroid (accelerated-aging) mouse models. Subsequent independent groups have continued to use FOXO4-DRI as a research tool to probe senescence in various cultured cell types and animal systems. All of these findings are confined to in-vitro and animal research.

Mechanisms studied in the lab

• Disrupting FOXO4–p53: the peptide competitively interferes with the binding between FOXO4 and p53 within the cell nucleus.
• Releasing p53 to act: freeing p53 from FOXO4 is associated with its nuclear exclusion and the activation of a p53-dependent apoptotic program in senescent cells.
• Selective effect on senescent cells: in published models, this apoptosis was reported preferentially in senescent cells rather than healthy dividing cells.
• DRI design for stability: the D-retro-inverso architecture is used to improve the peptide’s resistance to degradation in experimental settings.

Research status

FOXO4-DRI remains an investigational compound studied only in the preclinical setting — cell cultures and laboratory animals. It has not been evaluated or approved by the FDA or any regulatory body for the diagnosis, treatment, prevention, or cure of any condition. It is not a medicine and is not intended for human or veterinary use.

Related research compounds

Bolt Peptide does not sell FOXO4-DRI; this article is provided purely for educational and reference purposes. Researchers interested in compounds studied in the broader field of aging and cellular biology can browse our research peptide catalog. You may also be interested in our explainer on Epithalon, another peptide studied in aging-related research contexts.

FAQ

Is FOXO4-DRI available to buy from Bolt Peptide? No. Bolt Peptide does not offer FOXO4-DRI. This page is educational only.

What does “senolytic” mean in this research? In the laboratory literature, “senolytic” describes a compound studied for its ability to selectively eliminate senescent cells. The term refers to a research mechanism observed in cell and animal models, not to any established human application.

Why is it called “D-retro-inverso”? Because the peptide’s sequence is reversed and constructed from D-amino acids (the mirror-image isomers of standard L-amino acids). Researchers use this design to help the peptide retain its target-binding shape while resisting enzymatic degradation.

References

1. Baar MP, et al. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. 2017.
2. Zhang C, et al. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From Expanded Human Chondrocytes. Front Bioeng Biotechnol. 2021.
3. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic FOXO4-DRI. Nat Commun. 2025.

For research use only. Not sold by Bolt Peptide. Not for human or animal consumption; not a drug, food, or supplement. Statements have not been evaluated by the FDA.